Oberland Capital, a healthcare-focused investment firm, has named Cecilia Gonzalo and Michael Bloom as partners. Previously, Gonzalo worked at Vatera Healthcare Partners where she was a managing director focused on investments in the biopharmaceutical industry, And, Bloom joined Oberland in 2013; prior to his appointment, he was a principal at the firm.
NEW YORK, Nov. 1, 2018 /PRNewswire/ — Oberland Capital, a healthcare focused investment firm with over $1.2 billion in capital commitments since inception, announced today the appointment of two new Partners, Cecilia Gonzalo and Michael Bloom.
Ms. Gonzalo joins Oberland Capital from Vatera Healthcare Partners, the venture capital and private equity investing arm of Vatera Holdings LLC, where she was a Managing Director focused on investments in the biopharmaceutical industry. Previously, Ms. Gonzalo was a Managing Director with Essex Woodlands, a healthcare-focused growth equity firm. Ms. Gonzalo also worked in the healthcare group of Warburg Pincus LLC, a global private equity firm, and at Goldman, Sachs & Co. earlier in her career. Ms. Gonzalo earned an A.B. in Biochemical Sciences from Harvard College and an M.B.A. from Harvard Business School.
Mr. Bloom joined Oberland Capital in 2013 as the firm’s first employee and has now been promoted from Principal to Partner. Prior to joining Oberland Capital, Mr. Bloom was a member of the investment team at Paul Capital in the firm’s healthcare royalty platform. Prior to joining Paul Capital, Mr. Bloom worked at the Frankel Group, a healthcare-focused consulting firm. Mr. Bloom earned his M.B.A. with honors from the Wharton School’s Healthcare Management Program and his B.A. from Colby College.
Oberland Capital also announced the hiring of CN Chen, Director of Quantitative Research, Daniel (“James”) James, Director of Business Development and Investor Relations, and the further expansion of its investment team with the hiring of Sarah Siber, Vice President, and Greg Certo, Associate.
About Oberland Capital
Oberland Capital, a private investment firm with over $1.2 billion in capital commitments since inception, is focused exclusively on investing in the global healthcare industry and specializes in flexible investment structures customized to meet the specific capital requirements and strategic objectives of transaction partners. Oberland Capital’s broad suite of financing solutions includes monetization of royalty streams, acquisition of future product revenues, creation of project-based financing structures, and investment in debt and equity securities. With a combination of deep industry knowledge and extensive structured finance experience, the Oberland Capital team has a history of creating value for its transaction partners. The firm was founded in 2013 by Jean-Pierre Naegeli and Andrew Rubinstein.